Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: hemoglobin A1c Clear all

Conditions: Endometrial Cancer
Interventions: Baseline Measures, Strength-Training, Mid-point Measures, Post-Study Measures; Other · Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diabetes Mellitus, Type 1
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: New Haven, Connecticut • Minneapolis, Minnesota

Conditions: Type 2 Diabetes
Interventions: Adapted Look Ahead Lifestyle Intervention; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Polypharmacy
Interventions: COMET; Other
Lead sponsor: Yale University; Other
Eligibility: 65 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Type 1 Diabetes, Hypoglycemia, High Blood Sugar
Interventions: Dexcom G6 Continuous Glucose Monitor; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years to 21 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity, Heart Health Markers
Interventions: GLP-1 Booster (GB); Dietary Supplement
Lead sponsor: Alpine Biotech LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes Mellitus, Gastroparesis With Diabetes Mellitus, Gastroparesis
Interventions: Pyloromyotomy; Procedure
Lead sponsor: Matthew Allemang; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Mellitus
Interventions: Well-controlled diabetic (WC), Poorly controlled diabetics (PC); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Houston, Texas • Seattle, Washington

Conditions: Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus
Interventions: Pioglitazone (PIO), Empagliflozin (EMPA); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Rochester, Minnesota • Pittsburgh, Pennsylvania

Conditions: Diabetes
Interventions: Diabetes Dashboard Intervention, Usual Diabetes Care; Behavioral
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Type 2 Diabetes
Interventions: automated telephone intervention vs. usual care; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 55 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 2 Diabetes
Interventions: Capillary HbA1c collection; Procedure
Lead sponsor: GRADE Study Group; Other
Eligibility: 30 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Phoenix, Arizona • Denver, Colorado • Honolulu, Hawaii + 2 more

Conditions: Gestational Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Blood Sugar; High, Overweight and Obesity, Fat Loss, GLP-1, Glucagon
Interventions: GB, Placebo; Dietary Supplement
Lead sponsor: Lawry Han; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Gestational Diabetes, Hyperglycemia
Interventions: Continuous glucose monitor, Oral Glucose Tolerance Test, Hemoglobin A1c; Device · Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine (HOE901), Neutral Protamine Hagedorn (NPH) insulin, Insulin lispro; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Sacramento, California • San Diego, California • Greenwood Village, Colorado + 5 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: HealthPartners Institute; Other
Eligibility: 16 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 2 Diabetes Mellitus, CKD and Albuminuria
Interventions: Dapagliflozin 10 mg, Saxagliptin 2.5 mg, Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 37
States / cities: Peoria, Arizona • Chula Vista, California • Concord, California + 34 more

Conditions: Type 2 Diabetes
Interventions: MOSAIC, Print Materials; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Birmingham, Alabama • Nashville, Tennessee

Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: Group Emotion Focused Behavioral Intervention (G-EFBI), Group - With Every Heartbeat is Life (G-WEHL); Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 2 Diabetes
Interventions: Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels; Other
Lead sponsor: Foundation for Atlanta Veterans Education and Research, Inc.; Other
Eligibility: 40 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Wounds and Injuries
Interventions: Samples will be collected; Procedure
Lead sponsor: Gayle Gordillo; Other
Eligibility: 18 Years to 69 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Columbus, Ohio

Conditions: Type 2 Diabetes
Interventions: Nateglinide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 28 participants
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes Mellitus, Type 2
Interventions: My Diabetes Care (MDC); Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Nashville, Tennessee

Search by objective public record fields.

Telehealth-Based Resistance Training Intervention for Endometrial Cancer Survivors

The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus

Multilevel Lifestyle Intervention to Improve Physical Function in Older Adults With Type 2 Diabetes

Care Planning for Older Persons With Multiple Conditions: Encouraging a Tailored Approach (COMET): Stage II

CGM Use in Poorly Controlled Youth With Type 1 Diabetes

Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans

Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes

Alveolar Bone Changes in Diabetes (ABCD) Study

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus

An RCT Evaluation of a Diabetes Dashboard Team Model in Primary Care

Impact of an Automated Telephone Intervention on Glycosylated Hemoglobin (HbA1c) in Type 2 Diabetes

The GRADE Capillary Blood Collection Pilot Study

Utility Of Hemoglobin A1C For The Diagnosis Of Gestational Diabetes

Glucagon Like Peptide 1 (GLP-1) Booster™ RCT Study

Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

MObile Support Adapted to Individual Contexts

Group Emotion-Focused Behavioral Intervention for Diabetes Distress/A1c in T2D.

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

Mechanisms Regulating Wound Vascularization

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

My Diabetes Care: A Scalability and Usability Study